LMB In The News

RSS feed of lmb-in-the-news posts

Sjors Scheres named by Nature as one of ten people who mattered in 2014


LMB group leader Sjors Scheres is profiled by Nature as one of its ten people of the year, for his work on bringing the cell’s molecular machines into sharper focus, with the use of cryo-EM. More…


Heptares Therapeutics granted key patents for GPCR-Focused Drug Discovery Platform

MRC Technology

Heptares Therapeutics, a leading G protein-coupled receptor (GPCR) structure-guided drug discovery company, has recently been granted multiple key patents in the USA. GPCRs are a superfamily of drug receptors linked to a wide range of human diseases and Heptares was founded in 2007 to develop and commercialise pioneering research from the LMB and the National Institute of Medical Research (NIMR) to find new medicines targeting GPCRs. Sir John Saville presented the inventors with a memento to mark the award of these key patents for the GPCR-focused drug discovery platform. More…


LMB’s Pat Edwards interviewed for the Long and Short magazine


Pat Edwards discusses her role in Research Support at the LMB and why the LMB is such a special place to work. More…


Synthetic enzymes hint at life without DNA or RNA

New Scientist

Enzymes that don’t exist in nature have been made from genetic material that doesn’t exist in nature either, called XNA, or xeno nucleic acid. New Scientist reports how the breakthrough from Philipp Holliger’s group at the LMB reinforces the possibility that life could evolve without DNA or RNA, the two self-replicating molecules considered indispensible for life on Earth. More…


Major synthetic life breakthrough as LMB scientists make the first artificial enzymes

The Independent

For the first time ever, researchers have made synthetic enzymes – the vital ingredients needed for life – from artificial genetic material that does not exist outside the laboratory. This milestone from Philipp Holliger’s group at the LMB could soon lead to new ways of developing drugs and medical treatments, as reported in the Independent.


SELPEPCON – an exciting technology platform developed by the LMB’s Mike Gait


A technology platform to deliver cargoes using arrays of cell penetrating peptides was developed by the LMB’s Mike Gait, to help treat muscular degenerative diseases such as Duchenne muscular dystrophy. Further developments on this SELPEPCON technology, which was patented by the MRC and is licenced to Cambridge Research Biochemicals, are highlighted here.


Madan Babu to give Colworth Medal Lecture on 1st December


Madan, from the LMB’s Structural Studies Division, will present his award lecture and receive the prestigious 2014 Colworth Medal at the Biochemical Society’s AGM, on Monday 1st December at Charles Darwin House, London. Anyone wishing to attend should register in advance here.


Scientists find first evidence of local clock in the brain


Research by groups at Imperial College London and Michael Hastings’ group at LMB have revealed how local body clocks control waking and sleeping. A master clock found in part of the brain called the suprachiasmatic nucleus (SCN) is thought to synchronise lots of ‘local’ clocks that regulate many aspects of our metabolism, for example in the liver. But until now scientists have not had sufficient evidence to demonstrate the existence of these local clocks in the brain or how they operate. More…


Crystal beauty: Illuminating the structure of matter

BBC News

The LMB has played a pivotal role in the development of X-ray crystallography and the inspirational work of crystallographic scientists from round the UK is showcased in an upcoming exhibition at the Royal Albert Hall. “Illuminating Atoms” presents a selection of photographs by Max Alexander, to celebrate the International Year of Crystallography. The exhibition can be viewed on the free open days on 15th, 16th and 29th November, or at performances until 7th December 2014. More…


Bicycle Therapeutics announces £20M million for drug development


Bicycle Therapeutics, founded as a spin out company from the LMB by Sir Greg Winter and Christian Heinis, has secured £20m equity financing to develop bicycle drug candidates for cancer treatment. The bio-therapeutics company has used its bicyclic peptide technology to discover a new class of drug candidates which are similar to antibodies but 100-fold smaller and manufactured using simple, economic chemical synthesis. More…